Floatz logo

Crisantaspase

Acute Lymphoblastic Leukemia

Instituto do Cancer do Estado de São Pauloprotein_peptidePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
65/ 100

Competitive context

246 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
PERIPHERAL BLOOD STEM CELLS, ALLOGENEIC, CD34 POSITIVE
Fred Hutchinson Cancer Center
Phase 2/3BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Crisantaspase is also rated in:

B-cell acute lymphoblastic leukemiaActive
BB
Indicative · Phase 3
71 / 100
View asset →
lymphoblastic lymphomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
leukemiaDormant
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →